SCHEMBL3223294

SCHEMBL3223294

CNC(=O)c1ccccc1-c1ccccc1

nearest known ligand 0.65

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 5/20 0.65
CHRNA4 P43681 5/20 0.65
CHRNB4 P30926 4/20 0.65
CHRNA3 P32297 4/20 0.65
BCAT2 O15382 1/20 0.57
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
GAA P10253 3/20 0.56
ALDH1A1 P00352 2/20 0.56
HTT P42858 2/20 0.56
POLB P06746 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
LMNA P02545 2/20 0.54
NPSR1 Q6W5P4 2/20 0.54
FGFR1 P11362 1/20 0.53
FGFR2 P21802 1/20 0.53
FGFR4 P22455 1/20 0.53
FGFR3 P22607 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15472559 0.92 CHRNB2 (0.56) CHRNB2CHRNA4CHRNB4CHRNA3BCAT2
SCHEMBL11410287 0.87 GAA (0.63) CHRNB2CHRNA4CHRNB4CHRNA3MEN1
SCHEMBL18806401 0.87 PDK2 (0.51) CHRNB2CHRNA4CHRNB4CHRNA3SMN1; SMN2
SCHEMBL29434886 0.85 HNF4A (0.66) CHRNB2CHRNA4CHRNB4CHRNA3BCAT2
SCHEMBL21590157 0.85 SLC6A4 (0.66) CHRNB2CHRNA4CHRNB4CHRNA3GAA
SCHEMBL28085560 0.85 HNF4A (0.51) CHRNB2CHRNA4CHRNB4CHRNA3BCAT2
SCHEMBL27577620 0.85 CHRNB2 (0.61) CHRNB2CHRNA4CHRNB4CHRNA3BCAT2
SCHEMBL7016554 0.84 CHRNB2 (0.56) CHRNB2CHRNA4CHRNB4CHRNA3BCAT2
SCHEMBL15074688 0.84 KAT6A (0.59) CHRNB2CHRNA4CHRNB4CHRNA3BCAT2
SCHEMBL29854234 0.84 HNF4A (0.50) CHRNB2CHRNA4CHRNB4CHRNA3BCAT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110072850-B 3-sulfonyl-5-aminopyridine-2, 4-diol APJ agonists 百时美施贵宝公司 2023-07-21 CN claimed
US-20240368173-A1 TRICYCLIC GPR65 MODULATORS Pathios Therapeutics Limited (GB) 2024-11-07 US disclosed
CN-114835599-B Preparation method of o-aryl benzamide compound 绍兴久孚新材料科技有限公司 2024-05-03 CN disclosed
EP-4253367-A1 NOVEL BENZAZEPINE SPIRO DERIVATIVE Shanghai Jemincare Pharmaceuticals Co., Ltd. (CN) 2023-10-04 EP disclosed
CN-110072850-B 3-sulfonyl-5-aminopyridine-2, 4-diol APJ agonists 百时美施贵宝公司 2023-07-21 CN disclosed
US-20230130980-A1 HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS TECHFIELDS PHARMA CO., LTD. (CN) 2023-04-27 US disclosed
CN-114835599-A Preparation method of o-aryl benzamide compound 绍兴久孚新材料科技有限公司 2022-08-02 CN disclosed
US-20220073508-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORPORATION (US) 2022-03-10 US disclosed
US-20180222921-A1 HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS PREMIER RESEARCH INTERNATIONAL, LLC 2018-08-09 US disclosed
CN-105073745-B glucosylceramide synthase inhibitors 建新公司 2018-06-29 CN disclosed
US-7488752-B2 nor-seco himbacine derivatives; thrombosis, anticoagulants, anticancer agents; antiinflammatory agents; anticholesterol agents; cardiovascular disorders; antiarrhythmia agents; antiischemic agents; strokes; antiarthritic agents SCHERING CORPORATION (US) 2009-02-10 US disclosed
EP-1472226-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-11-03 EP disclosed
EP-1383760-A1 BIARYLCARBOXAMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-01-28 EP disclosed
CN-1121859-C Process for preparing pharmaceutical composition for treatment or prevention hypertension SNAKYO CO LTD (JP) 2003-09-24 CN disclosed
WO-2003045921-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-06-05 WO disclosed
WO-2002090347-A1 AMIDE COMPOUNDS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-11-14 WO disclosed
US-6015925-A TREATING MYCOSIS POLA CHEMICAL INDUSTRIES, INC. (JP) 2000-01-18 US disclosed
US-5846990-A Substituted biphenyl isoxazole sulfonamides BRISTOL-MYERS SQUIBB CO. (US) 1998-12-08 US disclosed
CN-1192729-A Benzamide derivatives and their use as vasopressin antagonists FUJISAWA PHARMACEUTICAL CO (JP) 1998-09-09 CN disclosed
CN-1188645-A Process for preparing pharmaceutical composition for treatment or prevention hypertension SNAKYO CO LTD (JP) 1998-07-29 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368173-A1 TRICYCLIC GPR65 MODULATORS GPR65, GPR3, NR1H2 CHRNB2 147/4885CHRNA4 150/4885CHRNB4 158/4885
US-20180222921-A1 HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS SLC7A1, VIP, HPGDS CHRNB2 4750/4885CHRNA4 4880/4885CHRNB4 4828/4885
US-20230130980-A1 HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS SLC7A1, VIP, HPGDS CHRNB2 4750/4885CHRNA4 4880/4885CHRNB4 4828/4885
US-20220073508-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GBA1, GBA2, GAA CHRNB2 4559/4885CHRNA4 4613/4885CHRNB4 4674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.